AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06572813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib Injection
Description: Bortezomib Injection, a kind of chemotherapy drug
Study NCT06572813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: PD-1 antibody
Study NCT06572813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: Combination of oxaliplatin, fluorouracil, irinotecan, leucovorin calcium
Study NCT06622616 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: EVALUATE THE EFFECT OF ACHETA DOMESTICUS POWDER CONSUMPTION ON GLUCOSE HOMEOSTASIS AND INTESTINAL DYSBIOSIS
Description: The study will have two arms, the functional group with A. domesticus powder (n=60) and a placebo group that will take a vegetable protein powder with a similar macronutrient composition (n=60). This population will be classified according to sex and BMI, and their nutritional-metabolic status (insulin resistance or not).~The study will include analysis of phenotypic data collection (medical history, lifestyle, diet, etc.); biochemical data: glucose, lipid, iron profile, blood count, and analysis of inflammation markers; genotyping, epigenetic analysis (methylation and mi-RNAs), targeted metabolomics (glycome and tryptophan) and metagenomic analysis of stool (16s rRNA sequencing for taxonomic identification study). Using continuous monitoring devices (glucose monitoring using a sensor and physical activity using an activity bracelet), lifestyle parameters (physical activity, circadian rhythms, sleep, stress, etc.) and blood glucose will be evaluated.
Study NCT06126900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone medication intake reminder + educational and motivational text messaging
Description: The intervention includes the use of a smartphone-based medication intake reminder, along with two educational and motivational text messages during the therapy period.
Study NCT06622616 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EVALUATE THE EFFECT OF ACHETA DOMESTICUS POWDER CONSUMPTION ON GLUCOSE HOMEOSTASIS AND INTESTINAL DYSBIOSIS
Description: The study will have two arms, the functional group with A. domesticus powder (n=60) and a placebo group that will take a vegetable protein powder with a similar macronutrient composition (n=60). This population will be classified according to sex and BMI, and their nutritional-metabolic status (insulin resistance or not).~The study will include analysis of phenotypic data collection (medical history, lifestyle, diet, etc.); biochemical data: glucose, lipid, iron profile, blood count, and analysis of inflammation markers; genotyping, epigenetic analysis (methylation and mi-RNAs), targeted metabolomics (glycome and tryptophan) and metagenomic analysis of stool (16s rRNA sequencing for taxonomic identification study). Using continuous monitoring devices (glucose monitoring using a sensor and physical activity using an activity bracelet), lifestyle parameters (physical activity, circadian rhythms, sleep, stress, etc.) and blood glucose will be evaluated.
Study NCT06683690 — intervention group
Intervention type: PROCEDURE
Intervention: Measurement of TGF- β1 in leprosy patients
Description: Study TGF- β1gene polymorphism in leprosy patients, and Correlate their results with different types of leprosy before and after treatment.
Study NCT05912517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nipocalimab
Description: Nipocalimab will be administered as an intravenous infusion.
Study NCT05912517 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as an intravenous infusion.
Study NCT05455684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aticaprant
Description: Aticaprant will be administered orally as tablets.
Study NCT05455684 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally as tablets.
Study NCT04936308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive guselkumab as SC injection.
Study NCT04936308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo as SC injection.
Study NCT06047509 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Focal Laser Ablation
Description: Removal of cancerous tissue through the direct application of laser energy
Study NCT06010030 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Targeted Transcranial Direct Current Stimulation
Description: High-Definition-tDCS will be delivered via a battery-driven constant direct current stimulator (Soterix) using a 4x1 montage (1 central anodal electrode and 4 cathodal electrodes) arranged in a HD-cap. Anodal or sham tDCS will be administered.
Study NCT06010030 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Therapy
Description: Participants will receive either semantic or phonological focused speech therapy
Study NCT04855253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7777
Description: E7777 is a recombinant fusion toxin consisting of full-length human IL-2 fused to the catalytic domains of diphtheria toxin. E7777 is preferentially bound to and internalized by cells expressing the high affinity form (CD25+) of the IL-2 receptor.
Study NCT06525571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cysview
Description: Blue light cystoscopy uses hexyl aminolevulinate (HAL, branded in the United States as Cysview), a prodrug which accumulates in the bladder tumors and improves the tumor's visualization.
Study NCT06525571 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Karl Storz D-Light C Photodynamic Diagnostic (PDD) system
Description: Cystoscopy procedure
Study NCT06525571 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Karl Storz D-Light C Photodynamic Diagnostic (PDD) system
Description: Cystoscopy procedure
Study NCT05327114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nipocalimab
Description: Nipocalimab will be administered intravenously.
Study NCT05327114 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered intravenously.
Study NCT04883619 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered intravenously.
Study NCT04883619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nipocalimab
Description: Nipocalimab dose 1 and dose 2 will be administered intravenously.
Study NCT04883619 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard-of-care treatment
Description: Standard-of-care treatment including MMF or MPA and glucocorticoids will be administered intravenously through Week 52.
Study NCT04883619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard-of-care treatment
Description: Standard-of-care treatment including MMF or MPA and glucocorticoids will be administered intravenously through Week 52.
Study NCT05663645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health insurance educational guide
Description: The educational guide includes 4 content areas: 1) Definition of key insurance terms; 2) premiums, deductibles across the five 2023 health plans; 3) Summary of how premiums and deductibles can affect out of pocket costs; 4) Guide to finding in-network IVF providers and facilities.
Study NCT05244044 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehabilitation in primary care
Description: Pulmonary rehabilitation consists breathing exercises, exercise capacity, muscle strength and change towards an active lifestyle.
Study NCT04879940 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Merit Medical Embospheres
Description: Prostatic Artery Embolization will performed as an outpatient procedure in Interventional Radiology. Bilateral selective pelvic angiograms will be performed to localize the prostatic arteries. Cone-beam or 3D computed tomography (CT) will be performed prior to embolization, if technically feasible and necessary. Embolization will be performed using Merit Medical Embospheres.
Study NCT04879940 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Patients will undergo standard of care definitive radiation therapy.
Study NCT04918225 — intervention group
Intervention type: RADIATION
Intervention: Magnetic Resonance Imaging
Description: Encephalic (about 30 minutes\*)~* lesion location assessment: 3D FLAIR, 3DT1, 3DT2 (standard OFSEP protocol)~* lesion severity assessment: Axial magnetization transfer imaging (mt0, mt1)~* tract location assessment: 30 directions diffusion imaging (standard OFSEP protocol)~* B0 and B1 mapping to correct for B0 and B1 inhomogeneities~  ● Spinal cord (about 50 minutes\*)~* lesion location assessment: cervical and thoracic sagittal T2 TSE (0.7x0.7x2.5mm3), axial cervical MEDIC T2\* (0.7x0.7x3mm3), axial thoracic T2 (0.5x0.5x3mm3)~* lesion severity assessment: Axial magnetization transfer imaging (mt0, mt1, 0.7x0.7x3mm3) on the cervical cord and on the thoracic cord~* tract location assessment: performed from registration on atlas~* B0 and B1 mapping to correct for B0 and B1 inhomogeneities
Study NCT05630040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive vagus nerve stimulation
Description: Participants will take the VNS device home and asked to perform a daily VNS protocol designed to down regulate sympathetic nervous system activity for 6 weeks.
Study NCT05630040 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Non-invasive vagus nerve stimulation
Description: Participants will take the VNS device home and asked to perform a daily VNS protocol designed to down regulate sympathetic nervous system activity for 6 weeks.
Study NCT05630040 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Intervention
Description: Participants will take a placebo device home for 6 weeks and use daily.
Study NCT06453928 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid Closed Loop Insulin Pump System
Description: Patients will be started on an automated insulin delivery system.
Study NCT04918225 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neurological examination
Description: Global disability will be scored using the Expanded Disability Status Scale score
Study NCT04918225 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Multiple Sclerosis Functional Composite
Description: * Walking disability will be scored using the 25-foot timed-walked test~* Arm disability will be scored using the nine-hole peg test
Study NCT04918225 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Physiotherapist examination
Description: * American Society Injury. Association motor subscore for each limb~* The muscle strength using a dynamometer. Two muscle groups will be tested for the upper (elbow flexors and extensors) and lower limbs (hip flexors and ankle dorsiflexion).~* The Ashworth Scale and the Tardieu Scale to assess spasticity.~* 6 minutes walking test~* Fatigue Severity Scale~* MFIS : Modified Fatigue Impact Scale
Study NCT04417803 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sampling
Description: plasmatic sampling
Study NCT06078267 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioPumlonary Management System (CPM)
Description: The CPM Device measures and trends a variety of physiologic parameters including thoracic impedance, respiration rate, tidal volume, ECG (electrocardiogram), heart rate, and diastolic heart sounds, all in an unobtrusive patch form factor.
Study NCT05946317 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lingual nerve function assessed after removal of mandibular third molar with lingual split technique
Description: The lingual split technique is based on using chisel and hammer in bone removing. After the buccal and lingual flaps are raised and retracted. Two buccal bone cutting with horizontal cutting up between them are performed, The disto-lingual bone fragment is fractured inward by placing the cutting edge of the chisel at 45 degrees with the surface of the bone and directed towards the lower second premolar of the opposite side. By maintaining the cutting edge of the chisel parallel to the external oblique ridge, a few light taps with the mallet will separate the lingual plate from the rest of the alveolar bone. And it released from soft tissues, buccally force is applied to roll the whole tooth lingually. The neurological function of the lingual nerve was assessed after the demise of local anesthesia, then the location of the disorder and taste function and healing time are determined by sensory neurological tests on a graphic map that divides the tongue into sextants.
Study NCT05146427 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Slow-wave enhancement
Description: A headband that measures slow-wave activity during sleep and uses auditory stimulation to enhance slow waves using closed-loop auditory stimulation.
Study NCT05146427 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: A headband that measures slow-wave activity during sleep but has no auditory stimulation.
Study NCT04797182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avatrombopag
Description: avatrombopag,60 mg/d,po
Study NCT05370521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildacerfont
Description: Oral tablet formulation taken once daily.
Study NCT05370521 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-active dosage form taken once daily.
Study NCT05056142 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Anesthesia
Description: Patients will receive epidural analgesia with 15 ml isobaric bupivacaine 0.125% plus fentanyl 2 μg/mL.
Study NCT05056142 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Analgesia
Description: Patients will receive Spinal analgesia with 5 mg bupivacaine and 25 μg of fentanyl in a 2 ml volume.
Study NCT04828161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ensovibep
Description: IV on day 1 only.
Study NCT06254001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Bupropion will be added at doses of 150 mg to 300 mg per day in addition to nicotine replacement therapy, counseling and cognitive behavioral therapy
Study NCT06254001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine replacement therapy (Nicotine patches)
Description: Nicotine replacement therapy (Nicotine patches) plus counseling and cognitive behavioral therapy
Study NCT06254001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (Nicotine patches)
Description: Nicotine replacement therapy (Nicotine patches) plus counseling and cognitive behavioral therapy
Study NCT04828161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV on day 1 only.
Study NCT05280366 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Streamline Surgical System
Description: Completion of the Streamline Surgical System procedure
Study NCT05280366 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iStent Inject W
Description: Implantation of competitor device
Study NCT05370079 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Collection of biological sample (blood and/or CSF)
Description: Blood sample will be collected one time for each patient:~2 \*4ml of blood on dry tube 2 \*4ml of blood on EDTA tube~If cerebrospinal fluid (CSF) has been drawn for diagnosis, remaining sample available will be stored in the control cohort (1 ml).
Study NCT06502535 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: 15 g inulin once daily for 4 weeks.
Study NCT06502535 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potassium nitrate and inulin
Description: 1300 mg potassium nitrate once daily for 4 weeks and 15 g inulin once daily for 4 weeks.
Study NCT05915390 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: walnuts
Description: walnuts will provide 15% of the total energy
Study NCT05915390 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Habitual diet
Description: continue with habitual diet and abstain from walnuts
Study NCT06169124 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo archived tissue and blood sample collection
Study NCT06169124 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest Radiography
Description: Undergo chest x-ray
Study NCT06169124 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT and/or PET/CT
Study NCT06169098 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Auricular acupressure on the left ear
Description: Auricular acupressure is applied at the Kidney point on the left ear using a tape with a Vaccaria seed (2mm in diameter). After placement on this acupoint, apply consistent moderate pressure for 5 minutes.
Study NCT06169098 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Auricular acupressure on the right ear
Description: Auricular acupressure is applied at the Kidney point on the right ear using a tape with a Vaccaria seed (2mm in diameter). After placement on this acupoint, apply consistent moderate pressure for 5 minutes.
Study NCT06169098 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham auricular acupressure
Description: Sham auricular acupressure is applied at Kidney point on the left ear using a tape without any seed. After placement on this acupoint, apply consistent moderate pressure for 5 minutes.
Study NCT04400526 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: A video competition
Description: Each Individual/group will be required to produce a maximum of 2-minute video on one of the following themes: (1) the hazardous effects of drug especially less psychotropic drugs such as Cannabis, (2) encouraging messages to drug abusers, and (3) existing anti-drug services.
Study NCT04400526 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: A training workshop
Description: The workshop will last for 6 hours, and will be delivered by an experienced counsellor from C.H.O.I.C.E. The content of the workshop will include (1) hazardous effects of drug abuse especially less psychotropic drugs such as Cannabis, (2) signs and symptoms of drug abuse particularly less psychotropic drugs like Cannabis, (3) alternatives to drug abuse, (4) community resources available, and (5) how to refer drug abusers. Besides, all children will be taught to use the AWARD model for referrals in the workshop.
Study NCT04400526 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: A mass promotional campaign
Description: Children who complete the training workshop in phase 2 will be invited to join phase 3. They are encouraged to design their own promotional activities for community members in the targeted districts. The activities can be delivered by a group (a maximum of 5 ADAs per group) or by an individual. Types of activities can include but not limited to health talks, booths, outreaching activities, games, posters, leaflets and websites. Likewise, if the ADAs encounter any drug abuser in their social circles, the ADAs will be asked to deliver a brief advice based on the AWARD model.
Study NCT06169124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Given PO
Study NCT06169124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Given PO
Study NCT06169124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Given IM
Study NCT06169124 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06169124 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT05536102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLD
Description: 20mg/m2, day 1, q3w
Study NCT05536102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m2, day 1, q3w
Study NCT05536102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m2, days 1-14, q3w
Study NCT05536102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200 mg, day 1, q3w
Study NCT06451822 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mIntense L+AS
Description: The investigated dermal filler mIntense L+AS is intended to be used as a temporary filler, administered by intradermal or subcutaneous injections, to correct small skin defects, such as wrinkles or scars.
Study NCT04737330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab
Description: Secukinumab 300 mg s.c. at Baseline, Week 1, Week 2, Week 3, Week 4, Week 8, Week 12
Study NCT04737330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo s.c. at Baseline, Weeks 1, Week 2, Week 3, Week 4, Week 8, Week 12
Study NCT06112054 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clotild Smart Guidewire System (CSGS)
Description: In the current study, a commercially available CE marked guidewire will be used to direct a catheter through blood vessels while the Clotild® Smart Guidewire (study device) will only be used to perform electrophysiological measurements (via its sensors) in the blood vessels during peripheral endovascular procedures. It is thus designed for use as an adjunct to conventional angiographic procedure